Sotrovimab for COVID-19
41st treatment shown to reduce risk in
May 2023, now with p = 0.002 from 25 studies, recognized in 38 countries.
Efficacy is variant dependent.
No treatment is 100% effective. Protocols
combine treatments.
5,100+ studies for
110 treatments. c19early.org
|